Increasing threat of Gram-positive bacterial infections in the intensive care unit setting

Critical Care Medicine

Volumn 29, Issue 4 SUPPL., 2001, Pages

  McGowan J E , Jr ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Antimicrobial; Antimicrobial resistance; Healthcare associated infection

Indexed keywords

GLYCOPEPTIDE; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; GRAM POSITIVE BACTERIUM; HEALTH SURVEY; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035051893     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104001-00003     Document Type: Review

References (73)

1. Emerging nosocomial infections and antimicrobial resistance
2. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2
3. Assessment of the relationship between antimicrobial usage and susceptibility: Differences between the hospital and specific patient-care areas
4. Update in infectious diseases
5. The impact of changing pathogens of serious infections in hospitalized patients
6. Epidemiology of drug resistance: Implications for a post-antimicrobial era
7. Antibiotic-resistant bacteria and healthcare systems - Four steps for effective response
8. The threat of vancomycin resistance
9. Implications of vancomycin-resistant Staphylococcus aureus
10. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin
11. Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and Wales
12. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital
13. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50
14. Editorial response: Staphylococci vs. glycopeptides - How much are the battle lines changing?
15. Laboratory capacity to detect antimicrobial resistance, 1998
16. Vancomycin resistance in staphylococci
17. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
18. Emergence of vancomycin resistance in Staphylococcus aureus
19. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
20. The population impact of MRSA in a country: The national survey of MRSA in Wales, 1007
21. Survey of blood stream infections attributable to Gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
22. Methicillin-resistant Staphylococcus aureus: The other emerging resistant Gram-positive coccus among liver transplant recipients
23. Control of antimicrobial resistance in the health care system
24. Methicillin-resistant Staphylococcus aureus in the community: New battlefronts, or are the battles lost?
25. Increase in community-acquired methicillin-resistant Staphylococcus aureus at a naval medical center
26. Clonal features of community-acquired methicillin-resistant Staphylococcus aureus in children
27. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak
28. Prevalence of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the community
29. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients
30. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999
31. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease
32. Cross-Canada spread of methicillin-resistant Staphylococcus aureus via transplant organs
33. Editorial response: Community-acquired methicillin-resistant Staphylococcus aureus infections - Where do we go from here?
34. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California
35. Cigarette smoking and invasive pneumococcal disease
36. The drug-resistant pneumococcus: Clinical relevance, therapy, and prevention
37. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
38. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997-1998
39. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: Trend analysis
40. Clonally related penicillin-nonsusceptible Streptococcus pneumoniae serotype 14 from cases of meningitis in Salvador, Brazil
41. Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae
42. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents
43. Pneumococcal bacteremia associated with an infected central venous catheter
44. Drug-resistant Streptococcus pneumoniae: Rational antibiotic choices
45. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones: A growing concern
46. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
47. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
48. Emergence of vancomycin tolerance in Streptococcus pneumoniae
49. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis
50. 23-Valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: Double-blind randomised and placebo controlled trial
51. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae in southwestern Japan and correlation of penicillin-binding protein 2b and 2x mutations in susceptibilities of penicillin G and cefotaxime
52. Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes
53. Pneumococcal pneumonia in adults treated at University of Kentucky Medical Center, 1995-1998: Implications of pathogen resistance
54. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance
55. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
56. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
57. Vancomycin-resistant enterococcal infections
58. Prevalence and determinants of fecal colonization with vancomycin-resistant Enterococcus in hospitalized patients in the Netherlands
59. Control of an outbreak of vancomycin-resistant Enterococcus faecium in an oncology ward in South Africa: Effective use of limited resources
60. VRE in the Republic of Ireland: Clinical significance, characteristics, and molecular similarity of isolates
61. Prevalence and molecular epidemiology of glycopeptide-resistant enterococci in Belgian renal dialysis units
62. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia
63. Enterococcus faecium bacteremia - Does vancomycin resistance make a difference?
64. Controlling antimicrobial resistance: The role of infection control and antimicrobial use
65. Epidemiology and molecular biology of antimicrobial resistance in bacteria
66. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period
67. WHO warns that fight against drug resistance cannot rely on new antibacterials
68. Drug resistance and nosocomial infections: Epidemiology and prevention strategies
69. Guidelines for the control of methicillin-resistant Staphylococcus aureus